nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabrafenib—ABCG2—Dactinomycin—sarcoma	0.0886	0.167	CbGbCtD
Dabrafenib—ABCG2—Mitoxantrone—sarcoma	0.0793	0.149	CbGbCtD
Dabrafenib—ABCG2—Vincristine—sarcoma	0.0545	0.103	CbGbCtD
Dabrafenib—ABCG2—Etoposide—sarcoma	0.05	0.0942	CbGbCtD
Dabrafenib—CYP3A4—Thiotepa—sarcoma	0.0398	0.0751	CbGbCtD
Dabrafenib—ABCG2—Doxorubicin—sarcoma	0.0341	0.0643	CbGbCtD
Dabrafenib—ABCB1—Dactinomycin—sarcoma	0.0319	0.0602	CbGbCtD
Dabrafenib—ABCB1—Mitoxantrone—sarcoma	0.0286	0.0539	CbGbCtD
Dabrafenib—CYP2C8—Etoposide—sarcoma	0.0266	0.0502	CbGbCtD
Dabrafenib—ABCB1—Vincristine—sarcoma	0.0197	0.0371	CbGbCtD
Dabrafenib—ABCB1—Etoposide—sarcoma	0.018	0.034	CbGbCtD
Dabrafenib—CYP3A4—Mitoxantrone—sarcoma	0.0171	0.0323	CbGbCtD
Dabrafenib—ABCB1—Doxorubicin—sarcoma	0.0123	0.0232	CbGbCtD
Dabrafenib—CYP3A4—Vincristine—sarcoma	0.0118	0.0222	CbGbCtD
Dabrafenib—CYP3A4—Etoposide—sarcoma	0.0108	0.0204	CbGbCtD
Dabrafenib—CYP3A4—Doxorubicin—sarcoma	0.00737	0.0139	CbGbCtD
Dabrafenib—NEK11—uterus—sarcoma	0.00385	0.0532	CbGeAlD
Dabrafenib—SIK1—mammary gland—sarcoma	0.0031	0.0428	CbGeAlD
Dabrafenib—NEK11—testis—sarcoma	0.00279	0.0386	CbGeAlD
Dabrafenib—LIMK1—tendon—sarcoma	0.00241	0.0333	CbGeAlD
Dabrafenib—NEK11—lymph node—sarcoma	0.00202	0.028	CbGeAlD
Dabrafenib—LIMK1—testis—sarcoma	0.002	0.0276	CbGeAlD
Dabrafenib—SIK1—hematopoietic system—sarcoma	0.00189	0.0261	CbGeAlD
Dabrafenib—SLCO1B1—mammary gland—sarcoma	0.00184	0.0255	CbGeAlD
Dabrafenib—SIK1—connective tissue—sarcoma	0.00182	0.0251	CbGeAlD
Dabrafenib—RAF1—myometrium—sarcoma	0.00175	0.0242	CbGeAlD
Dabrafenib—BRAF—uterus—sarcoma	0.0017	0.0235	CbGeAlD
Dabrafenib—RAF1—embryo—sarcoma	0.00168	0.0232	CbGeAlD
Dabrafenib—SIK1—skin of body—sarcoma	0.00164	0.0227	CbGeAlD
Dabrafenib—RAF1—seminal vesicle—sarcoma	0.00158	0.0218	CbGeAlD
Dabrafenib—RAF1—hematopoietic system—sarcoma	0.0015	0.0207	CbGeAlD
Dabrafenib—BRAF—tendon—sarcoma	0.00149	0.0206	CbGeAlD
Dabrafenib—LIMK1—lymph node—sarcoma	0.00145	0.02	CbGeAlD
Dabrafenib—RAF1—connective tissue—sarcoma	0.00145	0.02	CbGeAlD
Dabrafenib—BRAF—bone marrow—sarcoma	0.00144	0.02	CbGeAlD
Dabrafenib—SIK1—cardiac atrium—sarcoma	0.00143	0.0198	CbGeAlD
Dabrafenib—SIK1—uterus—sarcoma	0.00142	0.0197	CbGeAlD
Dabrafenib—SIK1—lymphoid tissue—sarcoma	0.00133	0.0183	CbGeAlD
Dabrafenib—RAF1—smooth muscle tissue—sarcoma	0.00132	0.0183	CbGeAlD
Dabrafenib—RAF1—skin of body—sarcoma	0.00131	0.018	CbGeAlD
Dabrafenib—SIK1—tendon—sarcoma	0.00125	0.0172	CbGeAlD
Dabrafenib—BRAF—testis—sarcoma	0.00123	0.0171	CbGeAlD
Dabrafenib—SIK1—bone marrow—sarcoma	0.00121	0.0167	CbGeAlD
Dabrafenib—BRAF—liver—sarcoma	0.00117	0.0161	CbGeAlD
Dabrafenib—RAF1—cardiac atrium—sarcoma	0.00114	0.0157	CbGeAlD
Dabrafenib—RAF1—uterus—sarcoma	0.00113	0.0157	CbGeAlD
Dabrafenib—SLCO1B1—hematopoietic system—sarcoma	0.00112	0.0155	CbGeAlD
Dabrafenib—RAF1—lymphoid tissue—sarcoma	0.00106	0.0146	CbGeAlD
Dabrafenib—CYP2C8—mammary gland—sarcoma	0.00105	0.0145	CbGeAlD
Dabrafenib—SIK1—testis—sarcoma	0.00103	0.0143	CbGeAlD
Dabrafenib—SLCO1B3—liver—sarcoma	0.00101	0.0139	CbGeAlD
Dabrafenib—RAF1—tendon—sarcoma	0.000994	0.0137	CbGeAlD
Dabrafenib—SIK1—liver—sarcoma	0.000977	0.0135	CbGeAlD
Dabrafenib—RAF1—bone marrow—sarcoma	0.000963	0.0133	CbGeAlD
Dabrafenib—BRAF—lymph node—sarcoma	0.000895	0.0124	CbGeAlD
Dabrafenib—SLC22A8—hematopoietic system—sarcoma	0.000873	0.0121	CbGeAlD
Dabrafenib—RAF1—testis—sarcoma	0.000823	0.0114	CbGeAlD
Dabrafenib—RAF1—liver—sarcoma	0.000778	0.0107	CbGeAlD
Dabrafenib—SIK1—lymph node—sarcoma	0.000749	0.0104	CbGeAlD
Dabrafenib—ABCG2—myometrium—sarcoma	0.000723	0.00999	CbGeAlD
Dabrafenib—ABCG2—seminal vesicle—sarcoma	0.000653	0.00903	CbGeAlD
Dabrafenib—CYP2C8—hematopoietic system—sarcoma	0.000639	0.00882	CbGeAlD
Dabrafenib—RAF1—lymph node—sarcoma	0.000596	0.00824	CbGeAlD
Dabrafenib—SLCO1B1—liver—sarcoma	0.000582	0.00804	CbGeAlD
Dabrafenib—ABCG2—uterus—sarcoma	0.000469	0.00648	CbGeAlD
Dabrafenib—CYP3A4—hematopoietic system—sarcoma	0.000433	0.00598	CbGeAlD
Dabrafenib—ABCG2—bone marrow—sarcoma	0.000398	0.0055	CbGeAlD
Dabrafenib—ABCB1—myometrium—sarcoma	0.000357	0.00493	CbGeAlD
Dabrafenib—CYP2C8—testis—sarcoma	0.00035	0.00484	CbGeAlD
Dabrafenib—ABCB1—embryo—sarcoma	0.000343	0.00474	CbGeAlD
Dabrafenib—ABCG2—testis—sarcoma	0.00034	0.0047	CbGeAlD
Dabrafenib—CYP2C8—liver—sarcoma	0.000331	0.00457	CbGeAlD
Dabrafenib—ABCB1—seminal vesicle—sarcoma	0.000322	0.00445	CbGeAlD
Dabrafenib—ABCG2—liver—sarcoma	0.000322	0.00444	CbGeAlD
Dabrafenib—Nervous system disorder—Vincristine—sarcoma	0.000314	0.00165	CcSEcCtD
Dabrafenib—Decreased appetite—Thiotepa—sarcoma	0.000314	0.00165	CcSEcCtD
Dabrafenib—Thrombocytopenia—Vincristine—sarcoma	0.000313	0.00165	CcSEcCtD
Dabrafenib—Oedema—Mitoxantrone—sarcoma	0.000312	0.00164	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Thiotepa—sarcoma	0.000312	0.00164	CcSEcCtD
Dabrafenib—Decreased appetite—Dactinomycin—sarcoma	0.000311	0.00164	CcSEcCtD
Dabrafenib—Fatigue—Thiotepa—sarcoma	0.000311	0.00164	CcSEcCtD
Dabrafenib—Infection—Mitoxantrone—sarcoma	0.00031	0.00163	CcSEcCtD
Dabrafenib—Hyperhidrosis—Vincristine—sarcoma	0.000309	0.00163	CcSEcCtD
Dabrafenib—Dermatitis bullous—Epirubicin—sarcoma	0.000309	0.00163	CcSEcCtD
Dabrafenib—Fatigue—Dactinomycin—sarcoma	0.000309	0.00163	CcSEcCtD
Dabrafenib—Constipation—Thiotepa—sarcoma	0.000309	0.00162	CcSEcCtD
Dabrafenib—Back pain—Etoposide—sarcoma	0.000307	0.00162	CcSEcCtD
Dabrafenib—ABCB1—hematopoietic system—sarcoma	0.000306	0.00423	CbGeAlD
Dabrafenib—Muscle spasms—Etoposide—sarcoma	0.000305	0.00161	CcSEcCtD
Dabrafenib—Thrombocytopenia—Mitoxantrone—sarcoma	0.000305	0.00161	CcSEcCtD
Dabrafenib—Skin disorder—Mitoxantrone—sarcoma	0.000303	0.00159	CcSEcCtD
Dabrafenib—Cardiac failure congestive—Doxorubicin—sarcoma	0.000302	0.00159	CcSEcCtD
Dabrafenib—Hyperhidrosis—Mitoxantrone—sarcoma	0.000301	0.00159	CcSEcCtD
Dabrafenib—Hypotension—Vincristine—sarcoma	0.000299	0.00157	CcSEcCtD
Dabrafenib—Hyponatraemia—Epirubicin—sarcoma	0.000297	0.00156	CcSEcCtD
Dabrafenib—Renal failure acute—Doxorubicin—sarcoma	0.000296	0.00156	CcSEcCtD
Dabrafenib—Pain in extremity—Epirubicin—sarcoma	0.000296	0.00156	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Thiotepa—sarcoma	0.000295	0.00155	CcSEcCtD
Dabrafenib—Anaemia—Etoposide—sarcoma	0.000294	0.00155	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Dactinomycin—sarcoma	0.000293	0.00154	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Vincristine—sarcoma	0.000292	0.00154	CcSEcCtD
Dabrafenib—Hypotension—Mitoxantrone—sarcoma	0.000291	0.00153	CcSEcCtD
Dabrafenib—Insomnia—Vincristine—sarcoma	0.000289	0.00152	CcSEcCtD
Dabrafenib—Dermatitis bullous—Doxorubicin—sarcoma	0.000286	0.00151	CcSEcCtD
Dabrafenib—Abdominal pain—Thiotepa—sarcoma	0.000285	0.0015	CcSEcCtD
Dabrafenib—Body temperature increased—Thiotepa—sarcoma	0.000285	0.0015	CcSEcCtD
Dabrafenib—Leukopenia—Etoposide—sarcoma	0.000284	0.0015	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Mitoxantrone—sarcoma	0.000284	0.00149	CcSEcCtD
Dabrafenib—Abdominal pain—Dactinomycin—sarcoma	0.000283	0.00149	CcSEcCtD
Dabrafenib—Body temperature increased—Dactinomycin—sarcoma	0.000283	0.00149	CcSEcCtD
Dabrafenib—Decreased appetite—Vincristine—sarcoma	0.000278	0.00146	CcSEcCtD
Dabrafenib—Cough—Etoposide—sarcoma	0.000277	0.00146	CcSEcCtD
Dabrafenib—Blood creatinine increased—Epirubicin—sarcoma	0.000277	0.00146	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Vincristine—sarcoma	0.000276	0.00145	CcSEcCtD
Dabrafenib—Fatigue—Vincristine—sarcoma	0.000276	0.00145	CcSEcCtD
Dabrafenib—Dehydration—Epirubicin—sarcoma	0.000275	0.00145	CcSEcCtD
Dabrafenib—Hyponatraemia—Doxorubicin—sarcoma	0.000275	0.00145	CcSEcCtD
Dabrafenib—Hypertension—Etoposide—sarcoma	0.000274	0.00144	CcSEcCtD
Dabrafenib—Constipation—Vincristine—sarcoma	0.000274	0.00144	CcSEcCtD
Dabrafenib—Pain in extremity—Doxorubicin—sarcoma	0.000274	0.00144	CcSEcCtD
Dabrafenib—Dry skin—Epirubicin—sarcoma	0.000271	0.00143	CcSEcCtD
Dabrafenib—Decreased appetite—Mitoxantrone—sarcoma	0.000271	0.00143	CcSEcCtD
Dabrafenib—Abdominal pain upper—Epirubicin—sarcoma	0.00027	0.00142	CcSEcCtD
Dabrafenib—Hypokalaemia—Epirubicin—sarcoma	0.000269	0.00142	CcSEcCtD
Dabrafenib—Fatigue—Mitoxantrone—sarcoma	0.000269	0.00141	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—sarcoma	0.000269	0.00141	CcSEcCtD
Dabrafenib—Constipation—Mitoxantrone—sarcoma	0.000266	0.0014	CcSEcCtD
Dabrafenib—Aspartate aminotransferase increased—Epirubicin—sarcoma	0.000266	0.0014	CcSEcCtD
Dabrafenib—Hypersensitivity—Thiotepa—sarcoma	0.000266	0.0014	CcSEcCtD
Dabrafenib—Nasopharyngitis—Epirubicin—sarcoma	0.000264	0.00139	CcSEcCtD
Dabrafenib—Hypersensitivity—Dactinomycin—sarcoma	0.000264	0.00139	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Vincristine—sarcoma	0.000262	0.00138	CcSEcCtD
Dabrafenib—Alanine aminotransferase increased—Epirubicin—sarcoma	0.000261	0.00137	CcSEcCtD
Dabrafenib—Asthenia—Thiotepa—sarcoma	0.000259	0.00136	CcSEcCtD
Dabrafenib—Infection—Etoposide—sarcoma	0.000258	0.00136	CcSEcCtD
Dabrafenib—Asthenia—Dactinomycin—sarcoma	0.000257	0.00135	CcSEcCtD
Dabrafenib—Blood creatinine increased—Doxorubicin—sarcoma	0.000256	0.00135	CcSEcCtD
Dabrafenib—Pruritus—Thiotepa—sarcoma	0.000255	0.00134	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Mitoxantrone—sarcoma	0.000255	0.00134	CcSEcCtD
Dabrafenib—Dehydration—Doxorubicin—sarcoma	0.000254	0.00134	CcSEcCtD
Dabrafenib—Thrombocytopenia—Etoposide—sarcoma	0.000254	0.00134	CcSEcCtD
Dabrafenib—Body temperature increased—Vincristine—sarcoma	0.000253	0.00133	CcSEcCtD
Dabrafenib—Abdominal pain—Vincristine—sarcoma	0.000253	0.00133	CcSEcCtD
Dabrafenib—Skin disorder—Etoposide—sarcoma	0.000252	0.00133	CcSEcCtD
Dabrafenib—Dry skin—Doxorubicin—sarcoma	0.000251	0.00132	CcSEcCtD
Dabrafenib—Hyperhidrosis—Etoposide—sarcoma	0.000251	0.00132	CcSEcCtD
Dabrafenib—Pancreatitis—Epirubicin—sarcoma	0.00025	0.00132	CcSEcCtD
Dabrafenib—Abdominal pain upper—Doxorubicin—sarcoma	0.00025	0.00132	CcSEcCtD
Dabrafenib—Hypokalaemia—Doxorubicin—sarcoma	0.000249	0.00131	CcSEcCtD
Dabrafenib—Diarrhoea—Thiotepa—sarcoma	0.000247	0.0013	CcSEcCtD
Dabrafenib—ABCG2—lymph node—sarcoma	0.000247	0.00341	CbGeAlD
Dabrafenib—Body temperature increased—Mitoxantrone—sarcoma	0.000246	0.0013	CcSEcCtD
Dabrafenib—Abdominal pain—Mitoxantrone—sarcoma	0.000246	0.0013	CcSEcCtD
Dabrafenib—Aspartate aminotransferase increased—Doxorubicin—sarcoma	0.000246	0.0013	CcSEcCtD
Dabrafenib—Diarrhoea—Dactinomycin—sarcoma	0.000245	0.00129	CcSEcCtD
Dabrafenib—Nasopharyngitis—Doxorubicin—sarcoma	0.000245	0.00129	CcSEcCtD
Dabrafenib—Hypotension—Etoposide—sarcoma	0.000242	0.00128	CcSEcCtD
Dabrafenib—Alanine aminotransferase increased—Doxorubicin—sarcoma	0.000241	0.00127	CcSEcCtD
Dabrafenib—Neutropenia—Epirubicin—sarcoma	0.000239	0.00126	CcSEcCtD
Dabrafenib—Dizziness—Thiotepa—sarcoma	0.000239	0.00126	CcSEcCtD
Dabrafenib—Hypersensitivity—Vincristine—sarcoma	0.000236	0.00124	CcSEcCtD
Dabrafenib—Pancreatitis—Doxorubicin—sarcoma	0.000232	0.00122	CcSEcCtD
Dabrafenib—ABCB1—uterus—sarcoma	0.000231	0.0032	CbGeAlD
Dabrafenib—Hyperglycaemia—Epirubicin—sarcoma	0.00023	0.00121	CcSEcCtD
Dabrafenib—Hypersensitivity—Mitoxantrone—sarcoma	0.00023	0.00121	CcSEcCtD
Dabrafenib—Asthenia—Vincristine—sarcoma	0.00023	0.00121	CcSEcCtD
Dabrafenib—Vomiting—Thiotepa—sarcoma	0.000229	0.00121	CcSEcCtD
Dabrafenib—Infestation NOS—Epirubicin—sarcoma	0.000228	0.0012	CcSEcCtD
Dabrafenib—Infestation—Epirubicin—sarcoma	0.000228	0.0012	CcSEcCtD
Dabrafenib—Vomiting—Dactinomycin—sarcoma	0.000228	0.0012	CcSEcCtD
Dabrafenib—Rash—Thiotepa—sarcoma	0.000228	0.0012	CcSEcCtD
Dabrafenib—Dermatitis—Thiotepa—sarcoma	0.000227	0.0012	CcSEcCtD
Dabrafenib—Headache—Thiotepa—sarcoma	0.000226	0.00119	CcSEcCtD
Dabrafenib—Rash—Dactinomycin—sarcoma	0.000226	0.00119	CcSEcCtD
Dabrafenib—Decreased appetite—Etoposide—sarcoma	0.000225	0.00119	CcSEcCtD
Dabrafenib—CYP3A4—liver—sarcoma	0.000224	0.0031	CbGeAlD
Dabrafenib—Renal failure—Epirubicin—sarcoma	0.000224	0.00118	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Etoposide—sarcoma	0.000224	0.00118	CcSEcCtD
Dabrafenib—Asthenia—Mitoxantrone—sarcoma	0.000224	0.00118	CcSEcCtD
Dabrafenib—Fatigue—Etoposide—sarcoma	0.000223	0.00118	CcSEcCtD
Dabrafenib—Stomatitis—Epirubicin—sarcoma	0.000222	0.00117	CcSEcCtD
Dabrafenib—Constipation—Etoposide—sarcoma	0.000222	0.00117	CcSEcCtD
Dabrafenib—Urinary tract infection—Epirubicin—sarcoma	0.000221	0.00117	CcSEcCtD
Dabrafenib—Neutropenia—Doxorubicin—sarcoma	0.000221	0.00116	CcSEcCtD
Dabrafenib—Diarrhoea—Vincristine—sarcoma	0.000219	0.00115	CcSEcCtD
Dabrafenib—Haematuria—Epirubicin—sarcoma	0.000217	0.00114	CcSEcCtD
Dabrafenib—ABCB1—lymphoid tissue—sarcoma	0.000216	0.00298	CbGeAlD
Dabrafenib—Epistaxis—Epirubicin—sarcoma	0.000215	0.00113	CcSEcCtD
Dabrafenib—Nausea—Thiotepa—sarcoma	0.000214	0.00113	CcSEcCtD
Dabrafenib—Hyperglycaemia—Doxorubicin—sarcoma	0.000213	0.00112	CcSEcCtD
Dabrafenib—Diarrhoea—Mitoxantrone—sarcoma	0.000213	0.00112	CcSEcCtD
Dabrafenib—Nausea—Dactinomycin—sarcoma	0.000213	0.00112	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Etoposide—sarcoma	0.000212	0.00112	CcSEcCtD
Dabrafenib—Dizziness—Vincristine—sarcoma	0.000212	0.00111	CcSEcCtD
Dabrafenib—Infestation NOS—Doxorubicin—sarcoma	0.000211	0.00111	CcSEcCtD
Dabrafenib—Infestation—Doxorubicin—sarcoma	0.000211	0.00111	CcSEcCtD
Dabrafenib—Renal failure—Doxorubicin—sarcoma	0.000207	0.00109	CcSEcCtD
Dabrafenib—Haemoglobin—Epirubicin—sarcoma	0.000206	0.00108	CcSEcCtD
Dabrafenib—Stomatitis—Doxorubicin—sarcoma	0.000205	0.00108	CcSEcCtD
Dabrafenib—Abdominal pain—Etoposide—sarcoma	0.000205	0.00108	CcSEcCtD
Dabrafenib—Body temperature increased—Etoposide—sarcoma	0.000205	0.00108	CcSEcCtD
Dabrafenib—Urinary tract infection—Doxorubicin—sarcoma	0.000205	0.00108	CcSEcCtD
Dabrafenib—Haemorrhage—Epirubicin—sarcoma	0.000205	0.00108	CcSEcCtD
Dabrafenib—Vomiting—Vincristine—sarcoma	0.000203	0.00107	CcSEcCtD
Dabrafenib—Urinary tract disorder—Epirubicin—sarcoma	0.000202	0.00106	CcSEcCtD
Dabrafenib—Rash—Vincristine—sarcoma	0.000202	0.00106	CcSEcCtD
Dabrafenib—Dermatitis—Vincristine—sarcoma	0.000202	0.00106	CcSEcCtD
Dabrafenib—Oedema peripheral—Epirubicin—sarcoma	0.000201	0.00106	CcSEcCtD
Dabrafenib—Haematuria—Doxorubicin—sarcoma	0.000201	0.00106	CcSEcCtD
Dabrafenib—Connective tissue disorder—Epirubicin—sarcoma	0.000201	0.00106	CcSEcCtD
Dabrafenib—Urethral disorder—Epirubicin—sarcoma	0.0002	0.00106	CcSEcCtD
Dabrafenib—Headache—Vincristine—sarcoma	0.0002	0.00106	CcSEcCtD
Dabrafenib—Epistaxis—Doxorubicin—sarcoma	0.000199	0.00105	CcSEcCtD
Dabrafenib—Vomiting—Mitoxantrone—sarcoma	0.000198	0.00104	CcSEcCtD
Dabrafenib—Rash—Mitoxantrone—sarcoma	0.000196	0.00103	CcSEcCtD
Dabrafenib—ABCB1—bone marrow—sarcoma	0.000196	0.00271	CbGeAlD
Dabrafenib—Dermatitis—Mitoxantrone—sarcoma	0.000196	0.00103	CcSEcCtD
Dabrafenib—Headache—Mitoxantrone—sarcoma	0.000195	0.00103	CcSEcCtD
Dabrafenib—Eye disorder—Epirubicin—sarcoma	0.000191	0.00101	CcSEcCtD
Dabrafenib—Hypersensitivity—Etoposide—sarcoma	0.000191	0.00101	CcSEcCtD
Dabrafenib—Haemoglobin—Doxorubicin—sarcoma	0.00019	0.001	CcSEcCtD
Dabrafenib—Nausea—Vincristine—sarcoma	0.00019	0.001	CcSEcCtD
Dabrafenib—Haemorrhage—Doxorubicin—sarcoma	0.000189	0.000996	CcSEcCtD
Dabrafenib—Urinary tract disorder—Doxorubicin—sarcoma	0.000187	0.000984	CcSEcCtD
Dabrafenib—Oedema peripheral—Doxorubicin—sarcoma	0.000186	0.000982	CcSEcCtD
Dabrafenib—Asthenia—Etoposide—sarcoma	0.000186	0.000979	CcSEcCtD
Dabrafenib—Connective tissue disorder—Doxorubicin—sarcoma	0.000186	0.000979	CcSEcCtD
Dabrafenib—Angiopathy—Epirubicin—sarcoma	0.000186	0.000977	CcSEcCtD
Dabrafenib—Urethral disorder—Doxorubicin—sarcoma	0.000185	0.000977	CcSEcCtD
Dabrafenib—Nausea—Mitoxantrone—sarcoma	0.000185	0.000975	CcSEcCtD
Dabrafenib—Immune system disorder—Epirubicin—sarcoma	0.000185	0.000973	CcSEcCtD
Dabrafenib—Mediastinal disorder—Epirubicin—sarcoma	0.000184	0.000971	CcSEcCtD
Dabrafenib—Chills—Epirubicin—sarcoma	0.000183	0.000966	CcSEcCtD
Dabrafenib—Pruritus—Etoposide—sarcoma	0.000183	0.000966	CcSEcCtD
Dabrafenib—Arrhythmia—Epirubicin—sarcoma	0.000183	0.000962	CcSEcCtD
Dabrafenib—Alopecia—Epirubicin—sarcoma	0.000181	0.000952	CcSEcCtD
Dabrafenib—Mental disorder—Epirubicin—sarcoma	0.000179	0.000943	CcSEcCtD
Dabrafenib—Malnutrition—Epirubicin—sarcoma	0.000178	0.000937	CcSEcCtD
Dabrafenib—Erythema—Epirubicin—sarcoma	0.000178	0.000937	CcSEcCtD
Dabrafenib—Diarrhoea—Etoposide—sarcoma	0.000177	0.000934	CcSEcCtD
Dabrafenib—Eye disorder—Doxorubicin—sarcoma	0.000177	0.000931	CcSEcCtD
Dabrafenib—Back pain—Epirubicin—sarcoma	0.000172	0.000907	CcSEcCtD
Dabrafenib—Angiopathy—Doxorubicin—sarcoma	0.000172	0.000904	CcSEcCtD
Dabrafenib—Dizziness—Etoposide—sarcoma	0.000171	0.000903	CcSEcCtD
Dabrafenib—Muscle spasms—Epirubicin—sarcoma	0.000171	0.000901	CcSEcCtD
Dabrafenib—Immune system disorder—Doxorubicin—sarcoma	0.000171	0.0009	CcSEcCtD
Dabrafenib—Mediastinal disorder—Doxorubicin—sarcoma	0.000171	0.000898	CcSEcCtD
Dabrafenib—Chills—Doxorubicin—sarcoma	0.00017	0.000894	CcSEcCtD
Dabrafenib—Arrhythmia—Doxorubicin—sarcoma	0.000169	0.00089	CcSEcCtD
Dabrafenib—ABCB1—testis—sarcoma	0.000168	0.00232	CbGeAlD
Dabrafenib—Vision blurred—Epirubicin—sarcoma	0.000168	0.000883	CcSEcCtD
Dabrafenib—Alopecia—Doxorubicin—sarcoma	0.000167	0.00088	CcSEcCtD
Dabrafenib—Mental disorder—Doxorubicin—sarcoma	0.000166	0.000873	CcSEcCtD
Dabrafenib—Vomiting—Etoposide—sarcoma	0.000165	0.000868	CcSEcCtD
Dabrafenib—Malnutrition—Doxorubicin—sarcoma	0.000165	0.000867	CcSEcCtD
Dabrafenib—Erythema—Doxorubicin—sarcoma	0.000165	0.000867	CcSEcCtD
Dabrafenib—Anaemia—Epirubicin—sarcoma	0.000165	0.000866	CcSEcCtD
Dabrafenib—Rash—Etoposide—sarcoma	0.000163	0.000861	CcSEcCtD
Dabrafenib—Dermatitis—Etoposide—sarcoma	0.000163	0.00086	CcSEcCtD
Dabrafenib—Headache—Etoposide—sarcoma	0.000162	0.000855	CcSEcCtD
Dabrafenib—Leukopenia—Epirubicin—sarcoma	0.000159	0.000839	CcSEcCtD
Dabrafenib—Back pain—Doxorubicin—sarcoma	0.000159	0.000839	CcSEcCtD
Dabrafenib—ABCB1—liver—sarcoma	0.000159	0.00219	CbGeAlD
Dabrafenib—Muscle spasms—Doxorubicin—sarcoma	0.000158	0.000834	CcSEcCtD
Dabrafenib—Cough—Epirubicin—sarcoma	0.000155	0.000818	CcSEcCtD
Dabrafenib—Vision blurred—Doxorubicin—sarcoma	0.000155	0.000817	CcSEcCtD
Dabrafenib—Nausea—Etoposide—sarcoma	0.000154	0.000811	CcSEcCtD
Dabrafenib—Hypertension—Epirubicin—sarcoma	0.000154	0.000809	CcSEcCtD
Dabrafenib—Anaemia—Doxorubicin—sarcoma	0.000152	0.000802	CcSEcCtD
Dabrafenib—Arthralgia—Epirubicin—sarcoma	0.000152	0.000798	CcSEcCtD
Dabrafenib—Myalgia—Epirubicin—sarcoma	0.000152	0.000798	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	0.000151	0.000793	CcSEcCtD
Dabrafenib—Dry mouth—Epirubicin—sarcoma	0.000148	0.000781	CcSEcCtD
Dabrafenib—Leukopenia—Doxorubicin—sarcoma	0.000147	0.000776	CcSEcCtD
Dabrafenib—Oedema—Epirubicin—sarcoma	0.000145	0.000765	CcSEcCtD
Dabrafenib—Infection—Epirubicin—sarcoma	0.000144	0.00076	CcSEcCtD
Dabrafenib—Cough—Doxorubicin—sarcoma	0.000144	0.000757	CcSEcCtD
Dabrafenib—Nervous system disorder—Epirubicin—sarcoma	0.000142	0.00075	CcSEcCtD
Dabrafenib—Thrombocytopenia—Epirubicin—sarcoma	0.000142	0.000749	CcSEcCtD
Dabrafenib—Hypertension—Doxorubicin—sarcoma	0.000142	0.000749	CcSEcCtD
Dabrafenib—Skin disorder—Epirubicin—sarcoma	0.000141	0.000743	CcSEcCtD
Dabrafenib—Hyperhidrosis—Epirubicin—sarcoma	0.00014	0.00074	CcSEcCtD
Dabrafenib—Myalgia—Doxorubicin—sarcoma	0.00014	0.000738	CcSEcCtD
Dabrafenib—Arthralgia—Doxorubicin—sarcoma	0.00014	0.000738	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	0.000139	0.000733	CcSEcCtD
Dabrafenib—Dry mouth—Doxorubicin—sarcoma	0.000137	0.000722	CcSEcCtD
Dabrafenib—Hypotension—Epirubicin—sarcoma	0.000136	0.000715	CcSEcCtD
Dabrafenib—Oedema—Doxorubicin—sarcoma	0.000134	0.000708	CcSEcCtD
Dabrafenib—Infection—Doxorubicin—sarcoma	0.000134	0.000703	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Epirubicin—sarcoma	0.000132	0.000697	CcSEcCtD
Dabrafenib—Nervous system disorder—Doxorubicin—sarcoma	0.000132	0.000694	CcSEcCtD
Dabrafenib—Thrombocytopenia—Doxorubicin—sarcoma	0.000132	0.000693	CcSEcCtD
Dabrafenib—Insomnia—Epirubicin—sarcoma	0.000131	0.000692	CcSEcCtD
Dabrafenib—Skin disorder—Doxorubicin—sarcoma	0.000131	0.000688	CcSEcCtD
Dabrafenib—Hyperhidrosis—Doxorubicin—sarcoma	0.00013	0.000684	CcSEcCtD
Dabrafenib—Decreased appetite—Epirubicin—sarcoma	0.000126	0.000665	CcSEcCtD
Dabrafenib—Hypotension—Doxorubicin—sarcoma	0.000126	0.000661	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Epirubicin—sarcoma	0.000125	0.000661	CcSEcCtD
Dabrafenib—Fatigue—Epirubicin—sarcoma	0.000125	0.00066	CcSEcCtD
Dabrafenib—Constipation—Epirubicin—sarcoma	0.000124	0.000654	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Doxorubicin—sarcoma	0.000122	0.000645	CcSEcCtD
Dabrafenib—ABCB1—lymph node—sarcoma	0.000122	0.00168	CbGeAlD
Dabrafenib—Insomnia—Doxorubicin—sarcoma	0.000122	0.00064	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Epirubicin—sarcoma	0.000119	0.000626	CcSEcCtD
Dabrafenib—Decreased appetite—Doxorubicin—sarcoma	0.000117	0.000615	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Doxorubicin—sarcoma	0.000116	0.000611	CcSEcCtD
Dabrafenib—Fatigue—Doxorubicin—sarcoma	0.000116	0.00061	CcSEcCtD
Dabrafenib—Constipation—Doxorubicin—sarcoma	0.000115	0.000605	CcSEcCtD
Dabrafenib—Abdominal pain—Epirubicin—sarcoma	0.000115	0.000605	CcSEcCtD
Dabrafenib—Body temperature increased—Epirubicin—sarcoma	0.000115	0.000605	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Doxorubicin—sarcoma	0.00011	0.000579	CcSEcCtD
Dabrafenib—Hypersensitivity—Epirubicin—sarcoma	0.000107	0.000564	CcSEcCtD
Dabrafenib—Abdominal pain—Doxorubicin—sarcoma	0.000106	0.00056	CcSEcCtD
Dabrafenib—Body temperature increased—Doxorubicin—sarcoma	0.000106	0.00056	CcSEcCtD
Dabrafenib—Asthenia—Epirubicin—sarcoma	0.000104	0.000549	CcSEcCtD
Dabrafenib—Pruritus—Epirubicin—sarcoma	0.000103	0.000541	CcSEcCtD
Dabrafenib—Diarrhoea—Epirubicin—sarcoma	9.94e-05	0.000523	CcSEcCtD
Dabrafenib—Hypersensitivity—Doxorubicin—sarcoma	9.9e-05	0.000522	CcSEcCtD
Dabrafenib—Asthenia—Doxorubicin—sarcoma	9.65e-05	0.000508	CcSEcCtD
Dabrafenib—Dizziness—Epirubicin—sarcoma	9.61e-05	0.000506	CcSEcCtD
Dabrafenib—Pruritus—Doxorubicin—sarcoma	9.51e-05	0.000501	CcSEcCtD
Dabrafenib—Vomiting—Epirubicin—sarcoma	9.24e-05	0.000486	CcSEcCtD
Dabrafenib—Diarrhoea—Doxorubicin—sarcoma	9.2e-05	0.000484	CcSEcCtD
Dabrafenib—Rash—Epirubicin—sarcoma	9.16e-05	0.000482	CcSEcCtD
Dabrafenib—Dermatitis—Epirubicin—sarcoma	9.15e-05	0.000482	CcSEcCtD
Dabrafenib—Headache—Epirubicin—sarcoma	9.1e-05	0.000479	CcSEcCtD
Dabrafenib—Dizziness—Doxorubicin—sarcoma	8.89e-05	0.000468	CcSEcCtD
Dabrafenib—Nausea—Epirubicin—sarcoma	8.63e-05	0.000454	CcSEcCtD
Dabrafenib—Vomiting—Doxorubicin—sarcoma	8.55e-05	0.00045	CcSEcCtD
Dabrafenib—Rash—Doxorubicin—sarcoma	8.48e-05	0.000446	CcSEcCtD
Dabrafenib—Dermatitis—Doxorubicin—sarcoma	8.47e-05	0.000446	CcSEcCtD
Dabrafenib—Headache—Doxorubicin—sarcoma	8.42e-05	0.000443	CcSEcCtD
Dabrafenib—Nausea—Doxorubicin—sarcoma	7.99e-05	0.00042	CcSEcCtD
Dabrafenib—SLCO1B3—Metabolism—ENO2—sarcoma	5.19e-05	0.00025	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR—EGFR—sarcoma	5.17e-05	0.00025	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—HBA1—sarcoma	5.16e-05	0.000249	CbGpPWpGaD
Dabrafenib—RAF1—MAPK Signaling Pathway—KRAS—sarcoma	5.14e-05	0.000248	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by NGF—EGFR—sarcoma	5.14e-05	0.000248	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR in Cancer—EGFR—sarcoma	5.13e-05	0.000247	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by PDGF—EGFR—sarcoma	5.11e-05	0.000246	CbGpPWpGaD
Dabrafenib—RAF1—Disease—NPM1—sarcoma	5.1e-05	0.000246	CbGpPWpGaD
Dabrafenib—RAF1—NGF signalling via TRKA from the plasma membrane—NRAS—sarcoma	5.08e-05	0.000245	CbGpPWpGaD
Dabrafenib—RAF1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—sarcoma	5.06e-05	0.000244	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by SCF-KIT—HRAS—sarcoma	5.03e-05	0.000243	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	5.02e-05	0.000242	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—MDM2—sarcoma	5e-05	0.000241	CbGpPWpGaD
Dabrafenib—RAF1—Platelet activation, signaling and aggregation—SRC—sarcoma	4.99e-05	0.000241	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—FOXO1—sarcoma	4.95e-05	0.000239	CbGpPWpGaD
Dabrafenib—RAF1—BDNF signaling pathway—HRAS—sarcoma	4.94e-05	0.000239	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—PDGFRB—sarcoma	4.94e-05	0.000238	CbGpPWpGaD
Dabrafenib—RAF1—Focal Adhesion—EGFR—sarcoma	4.93e-05	0.000238	CbGpPWpGaD
Dabrafenib—RAF1—Fc epsilon receptor (FCERI) signaling—KRAS—sarcoma	4.93e-05	0.000238	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR in disease—KRAS—sarcoma	4.93e-05	0.000238	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 interactions—KRAS—sarcoma	4.93e-05	0.000238	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	4.91e-05	0.000237	CbGpPWpGaD
Dabrafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—sarcoma	4.9e-05	0.000237	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR—KRAS—sarcoma	4.89e-05	0.000236	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—PDGFRA—sarcoma	4.86e-05	0.000235	CbGpPWpGaD
Dabrafenib—RAF1—Platelet activation, signaling and aggregation—VEGFA—sarcoma	4.86e-05	0.000234	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by NGF—KRAS—sarcoma	4.86e-05	0.000234	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR in Cancer—KRAS—sarcoma	4.84e-05	0.000234	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—VEGFC—sarcoma	4.83e-05	0.000233	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by PDGF—KRAS—sarcoma	4.82e-05	0.000233	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signaling of activated FGFR—HRAS—sarcoma	4.81e-05	0.000232	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—FOXO1—sarcoma	4.75e-05	0.000229	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—PDGFRB—sarcoma	4.74e-05	0.000229	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB4—HRAS—sarcoma	4.74e-05	0.000229	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—IL2—sarcoma	4.73e-05	0.000228	CbGpPWpGaD
Dabrafenib—LIMK1—Innate Immune System—HRAS—sarcoma	4.71e-05	0.000227	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—PDGFRA—sarcoma	4.67e-05	0.000225	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	4.64e-05	0.000224	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—KDR—sarcoma	4.63e-05	0.000224	CbGpPWpGaD
Dabrafenib—RAF1—NGF signalling via TRKA from the plasma membrane—EGFR—sarcoma	4.62e-05	0.000223	CbGpPWpGaD
Dabrafenib—RAF1—MAPK Signaling Pathway—TP53—sarcoma	4.57e-05	0.000221	CbGpPWpGaD
Dabrafenib—RAF1—Insulin Signaling—HRAS—sarcoma	4.55e-05	0.000219	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signal transduction—HRAS—sarcoma	4.52e-05	0.000218	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR—HRAS—sarcoma	4.5e-05	0.000217	CbGpPWpGaD
Dabrafenib—RAF1—EGF/EGFR Signaling Pathway—HRAS—sarcoma	4.5e-05	0.000217	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB2—HRAS—sarcoma	4.48e-05	0.000216	CbGpPWpGaD
Dabrafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—sarcoma	4.47e-05	0.000216	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—IL2—sarcoma	4.47e-05	0.000216	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 signaling—HRAS—sarcoma	4.46e-05	0.000215	CbGpPWpGaD
Dabrafenib—RAF1—Disease—ENO2—sarcoma	4.42e-05	0.000213	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—PLCG1—sarcoma	4.4e-05	0.000212	CbGpPWpGaD
Dabrafenib—RAF1—NGF signalling via TRKA from the plasma membrane—KRAS—sarcoma	4.37e-05	0.000211	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—JUN—sarcoma	4.34e-05	0.00021	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—CTNNB1—sarcoma	4.31e-05	0.000208	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—CXCR4—sarcoma	4.27e-05	0.000206	CbGpPWpGaD
Dabrafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—sarcoma	4.22e-05	0.000204	CbGpPWpGaD
Dabrafenib—BRAF—Neuronal System—HRAS—sarcoma	4.21e-05	0.000203	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 interactions—HRAS—sarcoma	4.19e-05	0.000202	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR in disease—HRAS—sarcoma	4.19e-05	0.000202	CbGpPWpGaD
Dabrafenib—RAF1—Fc epsilon receptor (FCERI) signaling—HRAS—sarcoma	4.19e-05	0.000202	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR—HRAS—sarcoma	4.15e-05	0.000201	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—PTPRC—sarcoma	4.15e-05	0.0002	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by NGF—HRAS—sarcoma	4.13e-05	0.000199	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	4.12e-05	0.000199	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR in Cancer—HRAS—sarcoma	4.12e-05	0.000199	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by PDGF—HRAS—sarcoma	4.1e-05	0.000198	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—CREB1—sarcoma	4.1e-05	0.000198	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—CREB1—sarcoma	4.06e-05	0.000196	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—PLCG1—sarcoma	4.06e-05	0.000196	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—SRC—sarcoma	4.06e-05	0.000196	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—NRAS—sarcoma	3.97e-05	0.000192	CbGpPWpGaD
Dabrafenib—RAF1—Focal Adhesion—HRAS—sarcoma	3.96e-05	0.000191	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TLE1—sarcoma	3.96e-05	0.000191	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—NRAS—sarcoma	3.9e-05	0.000188	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—SRC—sarcoma	3.9e-05	0.000188	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—FLT1—sarcoma	3.86e-05	0.000186	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—ATF1—sarcoma	3.86e-05	0.000186	CbGpPWpGaD
Dabrafenib—BRAF—Disease—FOXO1—sarcoma	3.84e-05	0.000186	CbGpPWpGaD
Dabrafenib—BRAF—Disease—PDGFRB—sarcoma	3.84e-05	0.000185	CbGpPWpGaD
Dabrafenib—RAF1—Transmission across Chemical Synapses—HRAS—sarcoma	3.8e-05	0.000183	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PLCG1—sarcoma	3.79e-05	0.000183	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—MMP2—sarcoma	3.78e-05	0.000183	CbGpPWpGaD
Dabrafenib—BRAF—Disease—PDGFRA—sarcoma	3.78e-05	0.000182	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—KIT—sarcoma	3.77e-05	0.000182	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—NRAS—sarcoma	3.75e-05	0.000181	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PLCG1—sarcoma	3.75e-05	0.000181	CbGpPWpGaD
Dabrafenib—RAF1—NGF signalling via TRKA from the plasma membrane—HRAS—sarcoma	3.71e-05	0.000179	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—SRC—sarcoma	3.67e-05	0.000177	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CXCR4—sarcoma	3.65e-05	0.000176	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—KIT—sarcoma	3.62e-05	0.000175	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—ATF1—sarcoma	3.6e-05	0.000174	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CXCR4—sarcoma	3.6e-05	0.000174	CbGpPWpGaD
Dabrafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—sarcoma	3.59e-05	0.000173	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—CREB1—sarcoma	3.59e-05	0.000173	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—VEGFA—sarcoma	3.58e-05	0.000173	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—EGFR—sarcoma	3.56e-05	0.000172	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—NRAS—sarcoma	3.53e-05	0.00017	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—ENO2—sarcoma	3.49e-05	0.000168	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—HBA1—sarcoma	3.46e-05	0.000167	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—CREB1—sarcoma	3.45e-05	0.000166	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—KRAS—sarcoma	3.42e-05	0.000165	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—EGFR—sarcoma	3.42e-05	0.000165	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	3.39e-05	0.000164	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—KRAS—sarcoma	3.36e-05	0.000162	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—VEGFC—sarcoma	3.34e-05	0.000161	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—ENO2—sarcoma	3.23e-05	0.000156	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—KRAS—sarcoma	3.23e-05	0.000156	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—EGFR—sarcoma	3.22e-05	0.000155	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—HBA1—sarcoma	3.21e-05	0.000155	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—KRAS—sarcoma	3.04e-05	0.000147	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—MDM2—sarcoma	2.97e-05	0.000143	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PLCG1—sarcoma	2.96e-05	0.000143	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	2.95e-05	0.000143	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	2.95e-05	0.000142	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—IL2—sarcoma	2.95e-05	0.000142	CbGpPWpGaD
Dabrafenib—BRAF—Disease—KIT—sarcoma	2.93e-05	0.000141	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	2.92e-05	0.000141	CbGpPWpGaD
Dabrafenib—RAF1—Neuronal System—HRAS—sarcoma	2.91e-05	0.000141	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—HRAS—sarcoma	2.9e-05	0.00014	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—CTNNB1—sarcoma	2.9e-05	0.00014	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—FOXO1—sarcoma	2.88e-05	0.000139	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—PDGFRB—sarcoma	2.88e-05	0.000139	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—HRAS—sarcoma	2.86e-05	0.000138	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—MDM2—sarcoma	2.85e-05	0.000138	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—PDGFRA—sarcoma	2.83e-05	0.000137	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—IGF1R—sarcoma	2.83e-05	0.000137	CbGpPWpGaD
Dabrafenib—BRAF—Disease—CREB1—sarcoma	2.79e-05	0.000135	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—HRAS—sarcoma	2.74e-05	0.000132	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PLCG1—sarcoma	2.74e-05	0.000132	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—FOXO1—sarcoma	2.69e-05	0.00013	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PDGFRB—sarcoma	2.69e-05	0.00013	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—FLT1—sarcoma	2.67e-05	0.000129	CbGpPWpGaD
Dabrafenib—RAF1—Disease—FOXO1—sarcoma	2.66e-05	0.000128	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PDGFRB—sarcoma	2.66e-05	0.000128	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PDGFRA—sarcoma	2.65e-05	0.000128	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	2.64e-05	0.000128	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PLCG1—sarcoma	2.63e-05	0.000127	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—SRC—sarcoma	2.62e-05	0.000126	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PDGFRA—sarcoma	2.61e-05	0.000126	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—HRAS—sarcoma	2.58e-05	0.000125	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—JUN—sarcoma	2.58e-05	0.000125	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	2.57e-05	0.000124	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—SRC—sarcoma	2.57e-05	0.000124	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—CTNNB1—sarcoma	2.56e-05	0.000124	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—VEGFA—sarcoma	2.55e-05	0.000123	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CXCR4—sarcoma	2.52e-05	0.000122	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—NRAS—sarcoma	2.52e-05	0.000122	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—VEGFA—sarcoma	2.5e-05	0.000121	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—ATF1—sarcoma	2.49e-05	0.00012	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—NRAS—sarcoma	2.47e-05	0.000119	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	2.37e-05	0.000114	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	2.32e-05	0.000112	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—SRC—sarcoma	2.31e-05	0.000112	CbGpPWpGaD
Dabrafenib—BRAF—Disease—MDM2—sarcoma	2.31e-05	0.000111	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—EGFR—sarcoma	2.3e-05	0.000111	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—CREB1—sarcoma	2.29e-05	0.00011	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—KDR—sarcoma	2.23e-05	0.000107	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—NRAS—sarcoma	2.23e-05	0.000107	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—SRC—sarcoma	2.22e-05	0.000107	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—KIT—sarcoma	2.2e-05	0.000106	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	2.19e-05	0.000106	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—KRAS—sarcoma	2.17e-05	0.000105	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—NRAS—sarcoma	2.14e-05	0.000103	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—KRAS—sarcoma	2.13e-05	0.000103	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CREB1—sarcoma	2.09e-05	0.000101	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—KIT—sarcoma	2.05e-05	9.9e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—EGFR—sarcoma	2.03e-05	9.79e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—KIT—sarcoma	2.03e-05	9.78e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ENO2—sarcoma	2e-05	9.67e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—HBA1—sarcoma	1.99e-05	9.61e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—CTNNB1—sarcoma	1.99e-05	9.6e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IGF1R—sarcoma	1.96e-05	9.44e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CREB1—sarcoma	1.95e-05	9.42e-05	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—EGFR—sarcoma	1.95e-05	9.4e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	1.95e-05	9.39e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CREB1—sarcoma	1.93e-05	9.31e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—KRAS—sarcoma	1.92e-05	9.25e-05	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—TP53—sarcoma	1.89e-05	9.13e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—FOXO1—sarcoma	1.86e-05	8.99e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PDGFRB—sarcoma	1.86e-05	8.97e-05	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—HRAS—sarcoma	1.84e-05	8.9e-05	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—KRAS—sarcoma	1.84e-05	8.88e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PDGFRA—sarcoma	1.83e-05	8.83e-05	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—HRAS—sarcoma	1.81e-05	8.73e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—SRC—sarcoma	1.8e-05	8.68e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—ENO2—sarcoma	1.74e-05	8.42e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—HBA1—sarcoma	1.73e-05	8.37e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—NRAS—sarcoma	1.73e-05	8.35e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—MDM2—sarcoma	1.73e-05	8.34e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PLCG1—sarcoma	1.7e-05	8.2e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—IL2—sarcoma	1.69e-05	8.16e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—HRAS—sarcoma	1.63e-05	7.86e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MDM2—sarcoma	1.62e-05	7.8e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—MYC—sarcoma	1.61e-05	7.78e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—MDM2—sarcoma	1.6e-05	7.7e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—EGFR—sarcoma	1.58e-05	7.61e-05	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—HRAS—sarcoma	1.56e-05	7.55e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL2—sarcoma	1.54e-05	7.46e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—KDR—sarcoma	1.54e-05	7.44e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—JUN—sarcoma	1.5e-05	7.25e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CTNNB1—sarcoma	1.49e-05	7.2e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—KRAS—sarcoma	1.49e-05	7.19e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PLCG1—sarcoma	1.48e-05	7.15e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—IL2—sarcoma	1.44e-05	6.97e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—KIT—sarcoma	1.42e-05	6.85e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—NRAS—sarcoma	1.42e-05	6.85e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CCND1—sarcoma	1.41e-05	6.79e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—JUN—sarcoma	1.4e-05	6.78e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CTNNB1—sarcoma	1.39e-05	6.73e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CTNNB1—sarcoma	1.38e-05	6.65e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CREB1—sarcoma	1.35e-05	6.52e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—SRC—sarcoma	1.35e-05	6.51e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—NRAS—sarcoma	1.3e-05	6.26e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—EGFR—sarcoma	1.29e-05	6.24e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—HRAS—sarcoma	1.27e-05	6.11e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—SRC—sarcoma	1.26e-05	6.08e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—SRC—sarcoma	1.24e-05	6.01e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—VEGFA—sarcoma	1.23e-05	5.92e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—KRAS—sarcoma	1.22e-05	5.9e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—NRAS—sarcoma	1.21e-05	5.85e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—NRAS—sarcoma	1.2e-05	5.78e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—EGFR—sarcoma	1.18e-05	5.7e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MYC—sarcoma	1.13e-05	5.45e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MDM2—sarcoma	1.12e-05	5.39e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—KRAS—sarcoma	1.12e-05	5.39e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—MYC—sarcoma	1.12e-05	5.38e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—EGFR—sarcoma	1.1e-05	5.33e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—EGFR—sarcoma	1.09e-05	5.26e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ENO2—sarcoma	1.08e-05	5.19e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—HBA1—sarcoma	1.07e-05	5.16e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—KRAS—sarcoma	1.04e-05	5.03e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—HRAS—sarcoma	1.04e-05	5.01e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—KRAS—sarcoma	1.03e-05	4.97e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IL2—sarcoma	9.99e-06	4.82e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CCND1—sarcoma	9.74e-06	4.7e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—JUN—sarcoma	9.72e-06	4.69e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CTNNB1—sarcoma	9.64e-06	4.65e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—HRAS—sarcoma	9.49e-06	4.58e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TP53—sarcoma	9.27e-06	4.47e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PLCG1—sarcoma	9.12e-06	4.4e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—HRAS—sarcoma	8.87e-06	4.28e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—HRAS—sarcoma	8.76e-06	4.23e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—SRC—sarcoma	8.72e-06	4.21e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—VEGFA—sarcoma	8.49e-06	4.1e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NRAS—sarcoma	8.38e-06	4.05e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MYC—sarcoma	7.81e-06	3.77e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—EGFR—sarcoma	7.64e-06	3.69e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—KRAS—sarcoma	7.22e-06	3.48e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TP53—sarcoma	6.41e-06	3.1e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—HRAS—sarcoma	6.13e-06	2.96e-05	CbGpPWpGaD
